Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Covington
UBS
Daiichi Sankyo
Fish and Richardson
Healthtrust
McKinsey
Cipla

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,649,180

« Back to Dashboard

Which drugs does patent 6,649,180 protect, and when does it expire?

Patent 6,649,180 protects DELZICOL and is included in one NDA.

This patent has seven patent family members in five countries.
Summary for Patent: 6,649,180
Title: Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups
Abstract:A cellulose ether film is formed of a composition comprising a cellulose ether as a base in which some of the hydrogen atoms of cellulosic hydroxyl groups are replaced by alkyl groups and/or hydroxyalkyl groups, a gelling agent, and a gelling aid. The total content of alkoxyl and hydroxyalkoxyl groups in the cellulose ether is limited to 23-37.6% by weight, which is effective for preventing the gelling aid from precipitating out and maintaining a favorable outer appearance during long-term storage.
Inventor(s): Matsuura; Seinosuke (Kyoto, JP), Tanjoh; Masaru (Sakurai, JP)
Assignee: Shionogi Qualicaps Co., Ltd. (Yamatokoriyama, JP)
Application Number:09/549,205
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,649,180
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 6,649,180

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apil DELZICOL mesalamine CAPSULE, DELAYED RELEASE;ORAL 204412-001 Feb 1, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,649,180

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11-106689Apr 14, 1999

International Family Members for US Patent 6,649,180

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 60001283 ➤ Try a Free Trial
European Patent Office 1045000 ➤ Try a Free Trial
Spain 2191595 ➤ Try a Free Trial
Japan 2000297102 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Medtronic
Queensland Health
McKinsey
Julphar
Fuji
Harvard Business School
QuintilesIMS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.